Vaginal Estradiol and Nicotine Interaction Profile

At a glance

  • What causes the enzyme effect / polycyclic aromatic hydrocarbons in smoke, not nicotine [1][2][3]
  • Estradiol label inducers / St. John's wort, phenobarbital, carbamazepine, rifampin [5][6]
  • Label mention of tobacco / listed as an arterial cardiovascular risk factor [4]
  • Estradiol 2-hydroxylation / 53.6% in smokers vs 35.1% in nonsmokers, one 1986 study [7]
  • Vaginal tablet absorption / 9.39 pg/mL on day 1 and 4.64 pg/mL by day 83 with the 10 mcg dose [8]
  • Nicotine handling / estrogen induces CYP2A6, most noticeable with oral contraceptives [9]
  • Vaginal cream contraindication / active DVT, PE or a history of either [4]

What do the estradiol labels say about smoking?

The vaginal product label used here is Estradiol Vaginal Cream 0.01%; vaginal tablets, rings and inserts are separate products with their own labeling. That cream label warns that systemic absorption may occur and that the warnings, precautions and adverse reactions tied to oral estrogen treatment should be taken into account [4].

The cream label lists tobacco use among the risk factors for arterial vascular disease [4]. The oral estradiol tablet label uses the same wording [5].

The CYP3A4 sections of the estradiol labels list St. John's wort, phenobarbital, carbamazepine and rifampin as inducers that may lower estrogen concentrations and reduce effect, and erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice as inhibitors that may raise them. Smoking and nicotine are not named there [5][6].

What does cigarette smoke do to estradiol?

One human study measured estradiol 2-hydroxylation in 14 premenopausal women who smoked at least 15 cigarettes a day and in 13 nonsmoking controls: 53.6% versus 35.1%, a rise of about 50% (P<0.001) [7]. That pathway produces 2-hydroxyestrogens, which have minimal peripheral estrogenic activity and are cleared quickly from the circulation [7].

The induction itself is credited to polycyclic aromatic hydrocarbons in tobacco smoke, which are potent inducers of CYP1A1 and CYP1A2 and possibly CYP2E1 [1][2].

A 1990 study looked at postmenopausal women. Baseline estrone, estradiol, estrone sulfate and estrone glucuronide were similar in smokers and nonsmokers, but unbound estradiol was significantly lower in the smokers (P<0.05) and sex-hormone-binding-globulin binding capacity was higher (P<0.001) [10]. After 1 or 2 mg of oral micronized estradiol, estrone and estradiol profiles were similar between groups and unbound estradiol was still significantly lower in smokers [10]. In that oral estradiol study, the smoking-related changes did not appear to require a higher dose to reach physiologic estrogen levels; the study did not test vaginal estradiol [10].

Does any of this apply to a vaginal product?

Absorption from a vaginal tablet was measured in 58 postmenopausal women with vaginal atrophy. Mean 24-hour average plasma estradiol was 9.39 pg/mL with the 10 mcg tablet and 19.84 pg/mL with the 25 mcg tablet on day 1, 6.56 and 18.29 pg/mL on day 14, and 4.64 and 9.41 pg/mL on day 83 [8]. With the 10 mcg dose, mean levels stayed inside the published postmenopausal reference range from the first day, which the study described as minimized estradiol absorption [8].

No study has measured estradiol levels, symptom response or endometrial change from a vaginal estradiol product in smokers compared with nonsmokers. How much the metabolic differences above would matter at these low circulating levels is therefore unmeasured.

Does nicotine itself change anything?

Nicotine replacement is a different exposure from smoke. A review of smoking cessation states that the enzyme effect is not related to the nicotine component of tobacco and that nicotine replacement will not alter it [3]. The combustion products, the polycyclic aromatic hydrocarbons, are what induce CYP1A1 and CYP1A2 [1][2].

Animal work adds a small caveat. A single 2.5 mg/kg subcutaneous dose of nicotine in rats raised lung CYP1A1 activity 4.4-fold at 6 hours and 14.7-fold at 12 hours, back near control by 24 hours, but did not significantly change liver CYP1A2 protein or its mRNA [11]. Human relevance is unknown.

On the cardiovascular side, nicotine may contribute to cardiovascular disease through sympathetic stimulation and catecholamine release [12]. A review of nicotine's cardiovascular toxicity notes that cigarette smoking increases blood coagulability, whereas transdermal nicotine does not appear to [12].

Does estrogen change nicotine levels?

In the other direction, estrogen induces CYP2A6, the enzyme that handles nicotine. Nicotine concentrations are lower in women than in men, an effect described as most pronounced in women taking oral contraceptives [9].

What does the cream label say about clots?

Estradiol Vaginal Cream 0.01% is contraindicated in women with active DVT or PE, or a history of either, and in women with active arterial thromboembolic disease such as stroke or myocardial infarction, or a history of it [4]. The cream label carries the older, longer boxed warning covering endometrial cancer, cardiovascular disorders, breast cancer and probable dementia [4].

Does quitting smoking change how estradiol is handled?

In 12 people smoking 20 or more cigarettes a day, abrupt cessation lowered caffeine clearance, a CYP1A2 marker, by 36.1%, with an apparent half-life of the decline of 38.6 hours (95% CI 27.4 to 54.4) [14]. That study measured enzyme activity, not estradiol levels.

Frequently asked questions

Does smoking make vaginal estradiol less effective?
The closest measurements are metabolic and come from other settings. In one 1986 study, estradiol 2-hydroxylation was 53.6% in women smoking at least 15 cigarettes a day versus 35.1% in nonsmokers [7]. In a 1990 study, unbound estradiol was significantly lower in postmenopausal smokers after oral micronized estradiol, but the changes did not appear to require a higher estrogen dose to reach physiologic levels [10].
Do nicotine patches or gum affect estradiol the way cigarettes do?
The induction is attributed to polycyclic aromatic hydrocarbons in tobacco smoke, not to nicotine, and a review of smoking cessation states that nicotine replacement will not alter that enzyme effect [2][3].
Does estrogen change nicotine levels?
Estrogen induces CYP2A6, the enzyme that metabolizes nicotine, and the effect is described as most pronounced in women taking oral contraceptives [9].
What does the vaginal estradiol label say about tobacco use?
The Estradiol Vaginal Cream 0.01% label lists tobacco use among arterial cardiovascular risk factors [4]. It also contraindicates the cream in women with active DVT or PE or a history of either, and with active arterial thromboembolic disease or a history of it [4].
How fast does the smoking enzyme effect wear off after quitting?
In 12 people smoking 20 or more cigarettes a day, caffeine clearance fell 36.1% after abrupt cessation, with an apparent half-life of 38.6 hours (95% CI 27.4 to 54.4) [14].
How much estradiol does a vaginal tablet put into the blood?
In 58 postmenopausal women with vaginal atrophy, mean 24-hour average plasma estradiol was 9.39 pg/mL with the 10 mcg tablet and 19.84 pg/mL with the 25 mcg tablet on day 1, falling to 4.64 and 9.41 pg/mL by day 83 [8].

References

  1. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36(6):425-38. Drug interactions with tobacco smoking. An update
  2. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-21. Drug interactions with smoking
  3. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs. 2009;18(11):1533-40. A review of smoking cessation: potentially risky effects on prescribed medications
  4. U.S. National Library of Medicine, DailyMed. Estradiol Vaginal (vaginal) prescribing information. Estradiol Vaginal (vaginal) label
  5. U.S. National Library of Medicine, DailyMed. Estradiol tablets USP (Teva) prescribing information. Estradiol tablets USP (Teva) label
  6. U.S. National Library of Medicine, DailyMed. Climara estradiol transdermal system (Bayer) prescribing information. Climara estradiol transdermal system (Bayer) label
  7. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 1986;315(21):1305-9. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking
  8. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13(3):219-27. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets
  9. Anderson GD, Chan LN. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin Pharmacokinet. 2016;55(11):1353-1368. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products
  10. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ, Lobo RA. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol. 1990;163(6 Pt 1):1953-60. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women
  11. Iba MM, Scholl H, Fung J, Thomas PE, Alam J. Induction of pulmonary CYP1A1 by nicotine. Xenobiotica. 1998;28(9):827-43. Induction of pulmonary CYP1A1 by nicotine
  12. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29(7):1422-31. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy
  13. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
  14. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178-84. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
Evidence overview for Vaginal Estradiol and Nicotine Interaction Profile